Navigation Links
Effient(TM) is Now Available in Pharmacies
Date:8/5/2009

PARSIPPANY, N.J. and INDIANAPOLIS, Aug. 5 /PRNewswire-FirstCall/ -- Effient(TM) (prasugrel), a new antiplatelet medicine, is now available in pharmacies across the United States, Daiichi Sankyo, Inc. and Eli Lilly and Company (NYSE: LLY) announced today.

The U.S. Food and Drug Administration approved Effient tablets on July 10 for the reduction of thrombotic cardiovascular events (including stent thrombosis) in patients with acute coronary syndromes (ACS) who are managed with an artery-opening procedure known as percutaneous coronary intervention (PCI). PCI usually includes the placement of a stent to help keep the artery open.

"Before Effient was available, physicians and patients had limited antiplatelet therapy options. Effient is a new treatment option to help reduce an ACS patient's risk of having a heart attack or stent thrombosis after PCI," said Dr. Dean Kereiakes, medical director at The Christ Hospital Heart and Vascular Center in Cincinnati, OH. "Different patients respond differently to medications, so it's important to have multiple options for treating heart disease given how pervasive and costly this condition is in our society."

Effient helps keep blood platelets from clumping together and developing a blockage in an artery. Taking Effient along with aspirin after PCI has been shown to reduce the chances of having a cardiac event such as a heart attack or stent-related blood clots in patients with ACS. Bleeding is the most common side effect of Effient. Some bleeding can be life-threatening, and even fatal.

"We are excited about bringing Effient, to patients and their healthcare professionals," said Enrique Conterno, president of Lilly USA, LLC. "We will work closely with healthcare professionals to ensure they understand how Effient works and who the appropriate patients are to receive this innovative treatment."

"We recognize the need for practical patient support and education during this difficult time in patients' lives, following a major cardiovascular event and possibly having a stent placed in an artery," said Joe Pieroni, president and chief executive officer for Daiichi Sankyo, Inc. "We are dedicated to developing highly relevant, evidence-based programs to help patients recover as well as regain their health and confidence."

Important Safety Information about Effient

Antiplatelet medicines, including Effient, can increase the risk of bleeding. If patients have unexplained or excessive bleeding while on Effient, they should contact their doctor right away as some bleeding can be serious, and sometimes may lead to death. Patients should not take Effient if they have a stomach ulcer or other conditions that cause bleeding or if they have a history of stroke or "mini-stroke" (transient ischemic attack or TIA).

If patients are 75 or older, or if they weigh less than 132 pounds, or if they are taking anticoagulants (eg, warfarin) or taking NSAIDs (eg, ibuprofen or naproxen) for a long time, they should talk to their doctor, as they may be at an increased risk of bleeding.

If patients plan to have surgery or a dental procedure, they should tell their doctors that they are taking Effient.

Patients should not stop taking Effient without first talking to the doctor who prescribed it for them, as this may result in increased risk of a clot in their stent, a heart attack or death.

Patients should get medical attention right away if they develop any of the following unexpected symptoms: fever, weakness, yellowing of the skin or eyes, or if skin becomes very pale or dotted with purple spots. These symptoms may be signs of a rare but potentially life-threatening condition called TTP, which has been reported with other medicines in this class.

For more information about Effient, including prescribing information, please visit www.Effient.com.

About Daiichi Sankyo

A global pharmaceutical innovator, Daiichi Sankyo Co., Ltd., was established in 2005 through the merger of two leading Japanese pharmaceutical companies. This integration created a more robust organization that allows for continuous development of novel drugs that enrich the quality of life for patients around the world. Areas of primary focus for Daiichi Sankyo research and development are thrombotic disorders, malignant neoplasm, diabetes mellitus, and autoimmune disorders. Equally important to the company are hypertension, hyperlipidemia or atherosclerosis, and bacterial infections. For more information, visit www.daiichisankyo.com.

Daiichi Sankyo, Inc., headquartered in Parsippany, New Jersey, is the U.S. subsidiary of Daiichi Sankyo Co., Ltd. For more information on Daiichi Sankyo, Inc., please visit www.dsi.com.

About Eli Lilly and Company

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs.

This press release contains certain forward-looking statements about Effient for the reduction of thrombotic cardiovascular events (including stent thrombosis) in patients with acute coronary syndromes who are managed with percutaneous coronary intervention and reflects Daiichi Sankyo's and Lilly's current beliefs. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of development and commercialization, including the risk of side effects and other safety concerns. There is no guarantee that the product will continue to be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly's filing with the United States Securities and Exchange Commission and Daiichi Sankyo's filings with the Tokyo Stock Exchange. Daiichi Sankyo and Lilly undertake no duty to update forward-looking statements.

Effient(TM) is a trademark of Eli Lilly and Company.

P-LLY

(Logo: http://www.newscom.com/cgi-bin/prnh/20061120/DSLLOGO)


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Daiichi Sankyo and Lilly Receive U.S. FDA Approval for Effient(TM)
2. College Mental Health Expert and Sister of Student Who Died By Suicide Available to Discuss College Mental Health Issues
3. Multi-Year Compendium of Pharmaceutical Case Studies Available from Best Practices, LLC
4. Tickets Still Available for Detroit Uncorked;
5. Proven Terumo Coronary Guidewire Technology Is Now Available in the United States
6. Experts, Advocates Available to Comment on Hillary Clintons Health Care Plan
7. Fingertip Formulary Mobile(TM) is Now Available for Physicians and Other Healthcare Providers Free on PDAs
8. New Resource for Taking Care of Aging Parents Available in Beta
9. 2007/2008 Pharmaceutical R&D Factbook Published by CMR International is Now Available
10. Morris Animal Foundation 2008 Sponsorship Guide Available, Details Current Animal Health Studies
11. Updated Brochure on Gynecologic Cancer Treatments Now Available
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... 2016 , ... 1105 Media’s Live From program has been ... competition. Live From won in the Use of Social Media category. The Folio: ... undertaken by the media industry’s most innovative marketing professionals. , Conceived ...
(Date:12/7/2016)... ... 2016 , ... Gensuite is honored to be selected as ... Product Launch category. Gensuite’s entry on their EZ Scan feature detailed the tool’s ... Training Group is a professional event and training provider based in the United ...
(Date:12/7/2016)... ... ... Road To Restoration”: an informative and enlightening book for those who believe that ... “The Road To Restoration” is the creation of published author, Thomas Fitzhugh Sheets, seventy-one-year-old ... you could reach out for, and grab, on the old carousels. If you ...
(Date:12/7/2016)... ... ... Rides a Train” allows readers to tag along on a special shopping trip for ... creation of published author, Janet Morrison, who has been writing mostly poetry, essays, professional ... series is her first attempt at writing for children. Janet, Fred, and two cats ...
(Date:12/7/2016)... ... December 07, 2016 , ... Dr. Greg ... the International Probiotic Association’s Washington DC workshop on November 2nd. The conference was ... dialog regarding probiotic dietary supplement regulations. , Dr. Leyer spoke about two ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... , Dec. 7, 2016 According to responses from ... than one-third (38%) of patients with non-small cell lung cancer ... factor receptor (EGFR) genetic mutation status. The findings of the ... LBA ID #6067 #P3.02b ) at the 2016 World ... . The survey results revealed an overall ...
(Date:12/7/2016)... Conn. , Dec. 7, 2016 ... II trial in patients with unresectable malignant pleural ... survival (PFS). The data, presented at the 17 ... in Vienna , showed nintedanib ... to placebo plus pemetrexed/cisplatin, with a significantly improved ...
(Date:12/7/2016)... Today, Stock-Callers.com presents four Biotech equities ... ), Anthera Pharmaceuticals Inc. (NASDAQ: ANTH ), ProNAi ... (NASDAQ: AVXS ). From its peak in July ... reach a level equal to what it saw at the ... for the year, it has still out-performed other market sectors, ...
Breaking Medicine Technology: